4.8 Article

Novel treatment strategies in rheumatoid arthritis

Journal

LANCET
Volume 389, Issue 10086, Pages 2338-2348

Publisher

ELSEVIER SCIENCE INC
DOI: 10.1016/S0140-6736(17)31491-5

Keywords

-

Funding

  1. AbbVie
  2. Bristol-Myers Squibb
  3. Pfizer
  4. Roche
  5. UCB
  6. MSD
  7. AstraZeneca
  8. Actelion
  9. Amgen
  10. Bayer
  11. Celgene
  12. Genzyme
  13. GlaxoSmithKline
  14. Janssen
  15. Lilly
  16. Merck
  17. Novartis
  18. Regeneron
  19. Sanofi
  20. Genentech

Ask authors/readers for more resources

New treatment strategies have substantially changed the course of rheumatoid arthritis. Many patients can achieve remission if the disease is recognised early and is treated promptly and continuously; however, some individuals do not respond adequately to treatment. Rapid diagnosis and a treat-to-target approach with tight monitoring and control, can increase the likelihood of remission in patients with rheumatoid arthritis. In this Series paper, we describe new insights into the management of rheumatoid arthritis with targeted therapy approaches using classic and novel medications, and outline the potential effects of precision medicine in this challenging disease. Articles are included that investigate the treat-to-target approach, which includes adding or de-escalating treatment. Rheumatoid arthritis treatment is impeded by delayed diagnosis, problematic access to specialists, and difficulties adhering to treat-to-target principles. Clinical management goals in rheumatoid arthritis include enabling rapid access to optimum diagnosis and care and the well informed use of multiple treatments approved for this disease.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.8
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available